Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 4 for:    PREFERE-
Previous Study | Return to List | Next Study

Evaluation of Four Treatment Modalities in Prostate Cancer With Low or "Early Intermediate" Risk (PREFERE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01717677
Recruitment Status : Terminated (Insufficient Recruitment)
First Posted : October 30, 2012
Last Update Posted : February 10, 2021
Sponsor:
Information provided by (Responsible Party):
Association of Urologic Oncology (AUO)

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
4arms preference based Study to compare four therapy options in prostate cancer with low or early intermediate risk

Condition or disease Intervention/treatment Phase
Prostate Cancer Procedure: radical prostatectomy Radiation: percutaneous radiation therapy Radiation: permanent seed implantation Procedure: Active Surveillance Not Applicable

Detailed Description:

The study will compare four possible therapy options for treatment of newly diagnosed prostate cancer with low or "early intermediate" risk according to the patients preferences.

The Following hypotheses will be tested:

  • Radiation is not relevantly worse compared to prostatectomy with regard to time to prostate cancer-related deaths
  • Permanent seed implantation therapy not inferior to prostatectomy with regard to time to prostate cancer-related deaths.
  • Active Surveillance does not lead to a significant decrease of time to prostate cancer-related deaths compared to prostatectomy.

That for patients with newly diagnosed prostate cancer will be randomized into one of the four treatment arms. Randomization may be limited to at least two of the four treatment arms if a patient refuses one or two of the four treatment arms according to his own preference.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 457 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Preference Based Randomized Trial for Evaluation of Four Treatment Modalities in Prostate Cancer With Low or "Early Intermediate" Risk
Study Start Date : October 2012
Actual Primary Completion Date : January 31, 2018
Actual Study Completion Date : April 30, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: radical prostatectomy
Procedure/Surgery: radical prostatectomy
 Procedure: radical prostatectomy
Experimental: percutaneous radiation therapy
Radiation: percutaneous radiation therapy
 Radiation: percutaneous radiation therapy
Experimental: permanent seed implantation
Radiation: permanent seed implantation
 Radiation: permanent seed implantation
Experimental: Active Surveillance
Procedure/Surgery: Active Surveillance
 Procedure: Active Surveillance


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Prostate cancer-specific survival [ Time Frame: minimal observation time of 13 years for last study patient ]

Secondary Outcome Measures :
  1. - Overall survival [ Time Frame: minimal observation time of 13 years for last study patient ]
  2. - Time to onset of hormone therapy [ Time Frame: 17 years ]
  3. - Occurrence of the first progression on hormone therapy [ Time Frame: 17 years ]
  4. - Quality of life on EORTC-QLQ-C30 with additional modul PCA (EORTCQLQ- PR25) as well as HADS-D at baseline [ Time Frame: before and 3 Mon. after therapy as well as after 1, 2, 3, 5, 7, 10 and 13 years ]
  5. - Complications / Safety [ Time Frame: median 15 years ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Newly diagnosed, biopsy proven adenocarcinoma of the prostate (ultrasound guided biopsy by standardized protocol)
  • Men aged 18-75 years
  • Recruitment within 3 months after histological confirmation
  • Localized prostata cancer <= cT2a, NX or N0 M0
  • PSA <= 10 ng / ml
  • Gleason score <= 7a (3 +4)
  • ECOG performance status 0 or 1
  • <= 30% positive biopsy cores with largest contiguous tumor length <= 5 mm
  • IPSS score < 18
  • Urine flow (Qmax):> 15 ml / s

Exclusion Criteria:

  • Unifocal Gleason 6 cancer <1mm
  • History of treatment for BPH e.g. TURP, HIFU or cryotherapy
  • History of radiation therapy to the pelvis
  • Life expectancy <10 years
  • ASA >= 4
  • Post-void residual urine > 50 ml
  • Prostate volume on transrectal ultrasound > 60 cm3
  • large median prostate lobe visualized on transrectal ultrasound
  • chronic intestinal inflammatory disease covering the rectum
  • Other active malignancy within the past 5 years (except for superficial basal cell carcinoma or non muscle infiltrating bladder carcinoma)
  • contraindications for prostatectomy, radiation therapy or Active Surveillance
  • Patients refusing written informed consent
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01717677


Locations
Layout table for location information
Germany
Universitätsklinikum
Ulm, Albert-Einstein-Allee 23, Germany, 89081
Universitätsklinikum
Homburg/Saar, Kirrberger Straße, Germany, 66424
Sponsors and Collaborators
Association of Urologic Oncology (AUO)
Investigators
Layout table for investigator information
Principal Investigator: Michael Stöckle, Prof. Dr. Klinik für Urologie und Kinderurologie der Universität des Saarlandes
Principal Investigator: Thomas Wiegel, Prof. Dr. Klinik für Strahlentherapie und Radioonkologie der Universität Ulm
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications of Results:

Layout table for additonal information
Responsible Party: Association of Urologic Oncology (AUO)
ClinicalTrials.gov Identifier: NCT01717677    
Other Study ID Numbers: AP 65/11
DRKS00004405 ( Registry Identifier: Freiburger Register )
First Posted: October 30, 2012    Key Record Dates
Last Update Posted: February 10, 2021
Last Verified: February 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
 Neoplasms by Site
Neoplasms
Prostatic Diseases